Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15791947 | 0.81 | HTR7 (0.36) | HTR7CYP11B2 | |
| SCHEMBL19136175 | 0.79 | CYP3A4 (0.43) | ALDH1A1CYP3A4POLBHTR7CYP11B2 | |
| SCHEMBL19179645 | 0.79 | CYP3A4 (0.42) | ALDH1A1TP53CYP3A4TSHRTDP1 | |
| SCHEMBL22326117 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TP53CYP3A4TSHRTDP1 | |
| SCHEMBL13711018 | 0.76 | CES2 (0.35) | HTR7 | |
| SCHEMBL14321440 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRPOLBHTR7SMN1; SMN2 | |
| SCHEMBL19179701 | 0.75 | ADRB2 (0.46) | ALDH1A1CYP3A4TSHRSMN1; SMN2KDM4E | |
| SCHEMBL19181766 | 0.75 | ADRB2 (0.46) | ALDH1A1CYP3A4TSHRSMN1; SMN2KDM4E | |
| SCHEMBL1814995 | 0.75 | GAA (0.41) | — | |
| SCHEMBL18518450 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TP53CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102177135-A | Acylaminobenzamide derivatives | BAYER CROPSCIENCE AG | 2011-09-07 | — | — | CN | disclosed |
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | ALDH1A1 271/4885TP53 3513/4885CYP3A4 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.